Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Community-Acquired Pneumonia (CAP)Pneumonia
Interventions
DIAGNOSTIC_TEST

The BIOFIRE®FILMARRAY® Pneumonia Panel

"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

lead

National Taiwan University Clinical Trial Center

OTHER

NCT06605352 - Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial | Biotech Hunter | Biotech Hunter